New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2013
10:11 EDTOLN, MOS, TDG, NXPI, MAIN, CTCM, B, AHL, FSYS, SNCR, ROVI, MTH, C, CNX, BBY, MT, GNW, SFD, REN, MAS, CLD, BDSI, BBVAOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ArcelorMittal (MT) upgraded to Buy from Neutral at UBS... Aspen Insurance (AHL) upgraded to Outperform from Neutral at Credit Suisse... Banco Bilbao (BBVA) upgraded to Hold from Sell at Societe Generale... Barnes Group (B) upgraded to Buy from Hold at KeyBanc... Best Buy (BBY) upgraded to Overweight from Neutral at Piper Jaffray... BioDelivery Sciences (BDSI) upgraded to Overweight from Neutral at Piper Jaffray... CONSOL Energy (CNX) upgraded to Outperform from Market Perform at BMO Capital... CTC Media (CTCM) upgraded to Neutral from Underperform at Credit Suisse... Citigroup (C) upgraded to Buy from Neutral at UBS... Cloud Peak Energy (CLD) upgraded to Outperform from Market Perform at BMO Capital... Main Street (MAIN) upgraded to Outperform from Neutral at RW Baird... Masco (MAS) upgraded to Outperform from Sector Perform at RBC Capital... Meritage Homes (MTH) upgraded to Strong Buy from Buy at ISI Group... NXP Semiconductors (NXPI) upgraded to Positive from Neutral at Susquehanna... Resolute Energy (REN) upgraded to Buy from Hold at Wunderlich... Rovi (ROVI) upgraded to Overweight from Neutral at Piper Jaffray... Smithfield Foods (SFD) upgraded to Neutral from Underperform at BofA/Merrill... TransDigm (TDG) upgraded to Buy from Hold at Deutsche Bank... Synchronoss (SNCR) upgraded to Outperform from Market Perform at Avondale... Mosaic (MOS) upgraded to Outperform from Sector Perform at Scotia Capital... Genworth (GNW) upgraded to Outperform from Underperform at Scotia Capital... Synchronoss (SNCR) upgraded to Outperform from Market Perform at Avondale... Fuel Systems (FSYS) upgraded to Neutral from Underperform at Macquarie... Olin Corp. (OLN) upgraded to Buy from Neutral at Monness Crespi.
News For MT;AHL;BBVA;BBY;B;BDSI;CNX;CTCM;CLD;C;MAIN;MAS;MTH;NXPI;REN;ROVI;TDG;SFD;SNCR;MOS;GNW;FSYS;OLN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 9, 2014
09:38 EDTCActive equity options trading
Subscribe for More Information
08:52 EDTNXPINXP Semiconductors price target raised to $80 from $75 at Morgan Stanley
Subscribe for More Information
08:24 EDTCCitigroup to sell Japanese consumer unit to Sumitomo Mitsui, Bloomberg says
Subscribe for More Information
07:04 EDTMAINMain Street to pay supplemental semi-annual cash cash dividend of 27.5c
Subscribe for More Information
05:59 EDTCCitigroup appointed successor depositary bank for Deutsche Post ADR program
Citi (C), acting through Citibank N.A., has been appointed by Deutsche Post AG (DPSGY) as successor depositary bank for its Level 1 American Depositary Receipt, or ADR, program. Deutsche Post DHL’s ADR program trades in the U.S. over the counter market, with each ordinary share equivalent to 1 ADR.
December 8, 2014
16:55 EDTCLone Star joins Springleaf as bidder for Citigroup OneMain unit, Bloomberg says
Subscribe for More Information
16:06 EDTNXPINXP Semiconductors initiated with an Outperform at Oppenheimer
Target $100.
16:00 EDTCOptions Update; December 8, 2014
Subscribe for More Information
15:40 EDTCLone Star joins Springleaf as bidder for Citigroup OneMain unit, Bloomberg says
07:01 EDTBDSIBioDelivery Sciences completes randomization in trial of clonidine topical gel
BioDelivery Sciences announced that it has completed the randomization of all patients in BDSI's ongoing initial pivotal Phase 3 clinical trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy. BDSI anticipates that topline results of the study will be available by the end of March 2015. The Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with PDN. In the trial, known as the RHAPSODY Study, subjects were randomized to receive either Clonidine Topical Gel or a placebo gel. Two hundred and sixty three adult subjects were randomized into the 12 week double-blind treatment phase of the study. This is the first of two pivotal trials that would be required for submission of a New Drug Application to the U.S. Food and Drug Administration. FDA has granted Fast Track designation for the program, which recognizes the need of developing new therapies for this serious condition. BDSI plans to begin the second Phase 3 study during the first quarter of 2015.
06:59 EDTCNXCONSOL removed from short-term buy list at Deutsche Bank
Deutsche Bank removed CONSOL from the short-term buy list due to an automatic six month demotion.
06:35 EDTCValue of Wall Street's M&A bankers has risen, NY Times says
The value of Wall Street's bankers who advise large companies seems to be increasing, while traders are becoming less valuable, according to The New York Times. Bankers who work on M&A deals are expecting their bonuses to increase, while traders anticipate that their compensation will drop, the newspaper added. Furthermore, banks seem to be going the extra mile to hire top notch bankers, the newspaper stated. Publicly traded large banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
06:21 EDTCDeadline for Petsmart bidders extended as lenders put on leash, NY Post reports
Subscribe for More Information
December 5, 2014
18:19 EDTCCitigroup's Japanese credit card business sought by three buyers, Nikkei says
Subscribe for More Information
11:23 EDTCOption volume leaders
Subscribe for More Information
09:36 EDTCActive equity options trading
Subscribe for More Information
08:41 EDTAHLAspen Insurance names Scott Kirk as CFO, effective immediately
Subscribe for More Information
December 4, 2014
07:38 EDTCMorgan Stanley Citigroup gaining share in capital markets, says Wells Fargo
Subscribe for More Information
05:32 EDTBBYBest Buy to sell Five Star business in China
Subscribe for More Information
December 3, 2014
16:00 EDTCOptions Update; December 3, 2014
iPath S&P 500 VIX Short-Term Futures down 45c to 26.52. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX C GILD RIG ABX according to Track Data.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use